Literature DB >> 10765070

Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density.

P H Schatteman1, L Hoekx, J J Wyndaele, W Jeuris, E Van Marck.   

Abstract

OBJECTIVE: Inflammation is a frequent histological finding in prostate biopsies, performed on men without prostatic malignancy or clinical prostatitis. We investigated the relationship between morphological parameters of inflammation in prostatic tissue and total serum prostate-specific antigen (PSA) and prostate-specific antigen density (PSAD) levels to determine if subclinical inflammation can cause elevation of PSA and PSAD.
METHODS: We reviewed 268 prostate biopsies, performed on 238 men with elevated PSA and/or abnormal digital rectal examination of the prostate. All premalignant and malignant biopsies and cases of clinical prostatitis were excluded. The inflammation in the remaining 145 prostate biopsies was scored for extent of inflammation and aggressiveness of inflammation, using the four-point scale designed by Irani and co-workers. In this prostatic inflammation scoring system, extent of inflammation is graded from 0 up to 3 according to the degree of invasion of inflammatory cells in prostatic tissue. Aggressiveness of inflammation is graded from 0 up to 3 according to the degree of contact or disruption of prostatic glandular epithelium by inflammatory cells.
RESULTS: Each of the studied biopsies showed inflammatory cells. Median PSA levels in grades 1, 2 and 3 of extent of inflammation were, respectively, 5.7, 6.8 and 13. 0. Median PSAD levels in these groups were 0.13, 0.16 and 0.33. There was no significant difference between these grades for PSA nor for PSAD. Median PSA levels in grades 0, 1 and 2 of aggressiveness of inflammation were, respectively, 3.9, 5.9 and 8.9. Median PSAD levels in these groups were 0.12, 0.18 and 0.17. For both parameters, there was a significant difference between grades (respectively, p = 0.0028 and p = 0.0330).
CONCLUSION: Inflammation of the prostate is a histological finding in almost every set of prostate biopsies, even when there are no signs of clinical prostatitis. This subclinical inflammation can cause PSA elevation. Not the extent of inflammation is of importance, but the disruption of epithelial integrity caused by the inflammatory infiltrate. When confronted with a patient with an elevated PSA level whose prostate biopsies reveal no malignancy but only inflammation, this concept can help in determining the need for quick repeat biopsies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10765070     DOI: 10.1159/000020161

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  41 in total

Review 1.  Histopathology reporting of prostate needle biopsies. 2005 update.

Authors:  Rodolfo Montironi; Remigio Vela Navarrete; Antonio Lopez-Beltran; Roberta Mazzucchelli; Gregor Mikuz; Aldo V Bono
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

2.  Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.

Authors:  Nagi B Kumar; Julio Pow-Sang; Kathleen M Egan; Philippe E Spiess; Shohreh Dickinson; Raoul Salup; Mohamed Helal; Jerry McLarty; Christopher R Williams; Fred Schreiber; Howard L Parnes; Said Sebti; Aslam Kazi; Loveleen Kang; Gwen Quinn; Tiffany Smith; Binglin Yue; Karen Diaz; Ganna Chornokur; Theresa Crocker; Michael J Schell
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

3.  The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis.

Authors:  Cuneyt Ozden; Ozdem Levent Ozdal; Ozer Guzel; Ozge Han; Selda Seckin; Ali Memis
Journal:  Int Urol Nephrol       Date:  2006-11-17       Impact factor: 2.370

Review 4.  Human microbiome and prostate cancer development: current insights into the prevention and treatment.

Authors:  Solmaz Ohadian Moghadam; Seyed Ali Momeni
Journal:  Front Med       Date:  2020-06-30       Impact factor: 4.592

5.  Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.

Authors:  M H Umbehr; B Gurel; T J Murtola; S Sutcliffe; S B Peskoe; C M Tangen; P J Goodman; I M Thompson; S M Lippman; M S Lucia; H L Parnes; C G Drake; W G Nelson; A M De Marzo; E A Platz
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-05       Impact factor: 5.554

6.  A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts.

Authors:  Elizabeth A Platz; Ibrahim Kulac; John R Barber; Charles G Drake; Corinne E Joshu; William G Nelson; M Scott Lucia; Eric A Klein; Scott M Lippman; Howard L Parnes; Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Angelo M De Marzo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-28       Impact factor: 4.254

7.  Testosterone regulates tight junction proteins and influences prostatic autoimmune responses.

Authors:  Jing Meng; Elahe A Mostaghel; Funda Vakar-Lopez; Bruce Montgomery; Larry True; Peter S Nelson
Journal:  Horm Cancer       Date:  2011-06       Impact factor: 3.869

8.  Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.

Authors:  Jennifer Rider Stark; Haojie Li; Peter Kraft; Tobias Kurth; Edward L Giovannucci; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

9.  Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection.

Authors:  Tomonori Kato; Akira Komiya; Akihiro Morii; Hiroaki Iida; Takatoshi Ito; Hideki Fuse
Journal:  Oncol Lett       Date:  2016-06-09       Impact factor: 2.967

10.  Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Authors:  Bora Gurel; M Scott Lucia; Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; Alan R Kristal; Howard L Parnes; Ashraful Hoque; Scott M Lippman; Siobhan Sutcliffe; Sarah B Peskoe; Charles G Drake; William G Nelson; Angelo M De Marzo; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-18       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.